Oxycaloxon

Active Ingredient:: Naloxone Hydrochloride, Oxycodone Hydrochloride
Origin:: EU

Oxycaloxon (Naloxone Hydrochloride, Oxycodone Hydrochloride)

International sale not permitted. Listed for the domestic market and B2B only.

Naloxone Hydrochloride, the active ingredient in Oxycaloxon, is an opioid antagonist presented as a combination formulation with Oxycodone Hydrochloride for oral use. It is used to reverse opioid overdose and to provide analgesia with reduced risk of respiratory depression in patients requiring strong pain relief.

GNH India supplies Oxycaloxon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Tad Pharma Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oxycaloxon combines opioid antagonist and opioid agonist activity to manage pain while mitigating overdose risk.

Acute severe pain: provides rapid, strong analgesia when other opioids are insufficient.
Post‑operative pain: maintains pain control after surgery with a built‑in safety mechanism.
Opioid‑induced respiratory depression risk: limits respiratory depression in patients receiving high‑dose opioids.

How It Works

Naloxone Hydrochloride competitively blocks mu‑opioid receptors, preventing activation by opioid agonists, while Oxycodone Hydrochloride activates the same receptors to produce analgesia. The fixed‑dose combination allows Oxycodone‑mediated pain relief to be rapidly reversed by the naloxone component if excessive opioid effect occurs, balancing efficacy with safety.

Side Effects

Adverse reactions may vary depending on the relative amounts of naloxone and oxycodone.

Common Side Effects

Nausea: mild to moderate upset stomach.
Dizziness: transient light‑headedness.
Constipation: reduced bowel motility.
Sweating: increased perspiration.
Headache: mild cranial discomfort.
Vomiting: occasional emesis.

Serious or Rare Side Effects

Respiratory depression: severe reduction in breathing rate.
Hypotension: marked drop in blood pressure.
Seizures: rare convulsive episodes.
Allergic reaction: rash, itching, swelling, or anaphylaxis.
Cardiac arrhythmia: irregular heart rhythm.
Hepatic dysfunction: elevated liver enzymes.

Precautions & Warnings

When prescribing Oxycaloxon, clinicians should consider patient‑specific factors and monitor for adverse events.

Assess renal and hepatic function: adjust use if impairment is present.
Evaluate opioid tolerance: ensure patient is opioid‑experienced before initiating therapy.
Monitor for respiratory depression: observe breathing especially after dose adjustments.
Avoid use with MAO inhibitors: increased risk of serotonin syndrome.
Counsel on dependence risk: educate patients about signs of misuse.
Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Oxycaloxon may interact with several drug classes, altering its safety or efficacy.

Major Interactions (Avoid)

Benzodiazepines: combined CNS depression can be life‑threatening.
CNS depressants: additive sedation and respiratory depression.
MAO inhibitors: risk of hypertensive crisis and serotonin syndrome.

Moderate Interactions (Monitor Closely)

CYP3A4 inhibitors (e.g., ketoconazole): may increase oxycodone levels.
CYP3A4 inducers (e.g., rifampicin): may reduce oxycodone efficacy.
Anticholinergics: may worsen constipation.
Diuretics: can enhance hypotensive effects.

Frequently Asked Questions

Oxycaloxon is a fixed‑dose combination of naloxone hydrochloride and oxycodone hydrochloride designed to provide strong analgesia for severe acute or post‑operative pain while incorporating a built‑in mechanism to reduce the risk of opioid‑induced respiratory depression.

Naloxone hydrochloride is an opioid antagonist that binds competitively to mu‑opioid receptors, blocking the effects of opioid agonists. In Oxycaloxon it is paired with oxycodone so that any excessive opioid activity can be rapidly reversed, helping to maintain a safer analgesic profile.

The specific dose of Oxycaloxon is determined by the prescribing clinician based on the patient’s pain severity, opioid tolerance, age, weight, and renal/hepatic function. Dosage regimens are individualized and should follow local prescribing guidelines.

Oxycaloxon should be used only if the potential benefit justifies the potential risk to the fetus or infant. Naloxone is generally considered low risk, but oxycodone crosses the placenta and is excreted in breast milk, so careful risk‑benefit assessment and specialist consultation are recommended.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Standard oxycodone provides potent analgesia but carries a higher risk of respiratory depression and misuse. Oxycaloxon adds naloxone, which can counteract excessive opioid effects, offering a safety advantage especially in patients at risk of overdose while delivering comparable pain relief.

Store Oxycaloxon tablets at ambient temperature, below 25 °C, in the original packaging. Protect from moisture, excessive heat and direct sunlight to maintain product stability.

Oxycaloxon is administered orally as a tablet. It should be taken with water, and dosing intervals are determined by the prescriber. Patients should follow the exact instructions provided by their healthcare professional.

The most serious risks include respiratory depression, severe hypotension, seizures, and allergic reactions such as anaphylaxis. Prompt medical attention is required if any of these events occur.

Oxycaloxon is contraindicated in patients with known hypersensitivity to naloxone, oxycodone or any excipients, in those receiving monoamine oxidase inhibitors, and in individuals with severe respiratory insufficiency or acute asthma attacks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 10 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.